( Of the ten patients evaluated all ten ...)Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO,Health

Of the ten patients evaluated, all ten patients completed four weeks, while seven of the ten patients completed eight weeks of therapy. Among the ten evaluable patients, there was one complete response (CR), one partial response (PR), and one patient with a 30% reduction in tumor volume.

Patients also underwent sequential biopsies of their tumors to evaluate biomarkers of hypoxia and angiogenesis. Paclitaxel causes an increase in tumor HIF-1alpha expression, which is downregulated by 2ME2. Changes were observed in HIF-1 regulated proteins, including tissue VEGF, VEGFR-2, plasma PAI-1, and osteopontin. Based on these findings, enrollment is continuing to further define the relationship between 2ME2 therapy and the effects on these biomarkers with the goal of identifying patients who would most benefit from 2ME2's unique mechanisms of action.

Carolyn F. Sidor, M.D., M.B.A, EntreMed Vice President and Chief Medical Officer, commented on the study, "Results to date are encouraging and further support EntreMed's rationale for using Panzem(R) NCD in combination with approved chemotherapeutics. Panzem(R) NCD's safety profile and lack of MDR chemoresistance offer opportunities for combining it with conventional chemotherapies to increase their effectiveness without increasing toxicity."

Dr. Sidor further commented, "Breast cancer remains a significant health problem, killing over 40,000 American women annually, despite the introduction of new therapies. A primary resistance mechanism to chemotherapeutic agents is thought to be the upregulation of HIF-1alpha and Panzem(R) is a potent inhibitor of HIF-1alpha. We hope that this study will also begin to identify biomarkers that we can use to further identify patients who would most benefit from treatment with Panzem(R) NCD."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference